Vertex Pharmaceuticals Stock Today
| VRTX Stock | USD 422.00 5.04 1.21% |
Performance0 of 100
| Odds Of DistressLess than 4
|
Vertex Pharmaceuticals is trading at 422.00 as of the 17th of January 2025; that is 1.21 percent increase since the beginning of the trading day. The stock's open price was 416.96. Vertex Pharmaceuticals has only four percent chance of going through some form of financial distress over the next 2 years, but has generated negative returns over the last 90 days. Note, on October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 1991 | Category Healthcare | Classification Health Care |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 257.53 M outstanding shares of which 3.96 M shares are at this time shorted by private and institutional investors with about 2.15 trading days to cover. More on Vertex Pharmaceuticals
Moving against Vertex Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Vertex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | MD FASN | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Composite, NASDAQ Biotechnology, ARCA Biotechnology, Nasdaq 100 Total, Dow Jones Biotechnology, NASDAQ 100 Pre, ARCA Institutional, NASDAQ Composite Total, NASDAQ Health Care, Nasdaq 100, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVertex Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceuticals' financial leverage. It provides some insight into what part of Vertex Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vertex Pharmaceuticals (VRTX) is traded on NASDAQ Exchange in USA. It is located in 50 Northern Avenue, Boston, MA, United States, 02210 and employs 5,400 people. Vertex Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 107.38 B. Vertex Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 257.53 M outstanding shares of which 3.96 M shares are at this time shorted by private and institutional investors with about 2.15 trading days to cover.
Vertex Pharmaceuticals currently holds about 9.77 B in cash with 3.54 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationVertex Pharmaceuticals shows a total of 257.53 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On October 8, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Vertex Pharmaceuticals's common stock.
Check Vertex Ownership Details
Vertex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Amundi | 2024-09-30 | 3.8 M | |
| Norges Bank | 2024-06-30 | 3.4 M | |
| Loomis, Sayles & Company Lp | 2024-09-30 | 3.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3 M | |
| Massachusetts Financial Services Company | 2024-09-30 | 2.9 M | |
| Bank Of America Corp | 2024-09-30 | 2.6 M | |
| Hhg Plc | 2024-09-30 | 2.5 M | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.4 M | |
| Northern Trust Corp | 2024-09-30 | 2.4 M | |
| Capital World Investors | 2024-09-30 | 26.8 M | |
| Vanguard Group Inc | 2024-09-30 | 23.2 M |
Vertex Pharmaceuticals Historical Income Statement
Vertex Stock Against Markets
Vertex Pharmaceuticals Corporate Management
| Jonathan JD | Executive Officer | Profile | |
| Stephanie Franklin | Senior Officer | Profile | |
| Mike Tirozzi | SVP Officer | Profile | |
| Damian Esq | Chief VP | Profile | |
| Ourania Tatsis | Ex Officer | Profile |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.